Gilead Sciences stock sits 2.32 percent below its yearly high

Published on 10/19/2026 at 09:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gilead schedules third-quarter results for October 29, 2026. Gilead Sciences stock costs EUR 139.49 on October 19, 2026, 0.47 percent above the Xetra close.

Guidance and reporting date

Second-quarter total product sales reached USD 7.60 billion on August 4, 2026.
Full-year HIV growth guidance rose to 9-10 percent from 8 percent in August 2026.
Gilead Sciences stock trades at EUR 139.49 at 9:34 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.47 percent above the Xetra close of October 16, 2026.
Third-quarter results are scheduled for October 29, 2026.

Aquarell der Foster City Skyline mit Biotech-Campus von Gilead Sciences am Wasser — Gilead Sciences Aquarell US3755581036 Skyline Foster City Biotech-Büropark mit Segelbooten am Morgen, Illustration mit AI erstellt.

Gilead Sciences (ISIN US3755581036) was trading at EUR 139.49 at Lang & Schwarz on October 19, 2026, at 9:34 a.m. CEST, 0.47 percent above the Xetra close of October 16, 2026 at EUR 138.84. The stock sits 2.32 percent below its EUR 142.80 52-week high, making the upcoming earnings date the key near-term reference.

Yahoo reported on October 15, 2026 that Gilead will release its third-quarter 2026 results after the market closes on October 29, 2026. Management is scheduled to host a webcast at 4:30 p.m. Eastern Time.

Second-quarter growth sets the baseline

Gilead's second-quarter total product sales reached USD 7.60 billion, an 8 percent year-over-year increase, according to the company's earnings call transcript carried by Yahoo on August 4, 2026. HIV sales rose 12 percent to USD 5.70 billion, while Trodelvy sales increased 26 percent to USD 457.00 million.

The quarter also changed the guidance framework. Gilead raised full-year HIV sales growth guidance to 9-10 percent from 8 percent, while full-year total product sales guidance stood at USD 30.10 billion to USD 30.40 billion.

What does October 29 mean for growth?

The next report will test whether the commercial momentum described in August carried into the third quarter. The PrEP business exceeded USD 1.00 billion in quarterly sales in the second quarter, and management cited a USD 4.00 billion annual run rate for the franchise.

Chronology gives investors three useful markers. On August 4, 2026, Gilead reported USD 7.60 billion in second-quarter total product sales and 12 percent HIV growth through Yahoo. On October 7, 2026, Truist Financial raised its target to USD 158.00, as reported by MarketBeat. On October 15, 2026, Gilead announced the October 29, 2026 reporting date through Yahoo.

Dates that frame the next move

The next two scheduled dates are October 29, 2026 for third-quarter results and October 29, 2026 at 4:30 p.m. Eastern Time for the management webcast. The release will provide the next detailed update on HIV, oncology, liver disease and cell therapy sales.

Stock stays near its yearly high

Gilead's EUR 139.49 indication is 2.32 percent below the EUR 142.80 52-week high and 40.96 percent above the EUR 98.96 low, both as of October 19, 2026. The market capitalization was EUR 173.4 billion, while the primary listing is Nasdaq in USD.

Gilead Sciences was trading at EUR 139.49 at Lang & Schwarz on October 19, 2026, at 9:34 a.m. CEST, 0.47 percent above the Xetra close of October 16, 2026 at EUR 138.84. The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.